23
total announcements
524372.BO · 15 min delayed
Orchid Pharma Ltd
Orchid Pharma Ltd has announced the Scrutinizer's Report and Voting Results for its 33rd Annual General Meeting held on September 29, 2026, through Video Conferencing (VC) or Other Audio-Visual Means (OAVM). The meeting was conducted in accordance with the Companies Act, 2013, and SEBI (LODR) Regulations 2015.
Orchid Pharma Ltd
Orchid Pharma Ltd held its 33rd Annual General Meeting on September 29, 2026, through video conferencing, with 32 members present. The meeting was chaired by Manish Dhanuka, Managing Director, after Ram Gopal Agarwal's absence. The company secretary informed the members about the auditors' report, which did not contain any qualification, but had certain qualifications in the consolidated auditor's report.
Orchid Pharma Ltd
Orchid Pharma Ltd has announced the closure of its trading window for the quarter ending September 30, 2026, due to the upcoming declaration of unaudited financial results.
Orchid Pharma Ltd
Orchid Pharma Ltd has informed about the trading approval of equity shares issued and allotted under the Scheme of Amalgamation, which have been listed and admitted to dealings on NSE and BSE with effect from September 23, 2026.
Orchid Pharma Ltd
Orchid Pharma Ltd has purchased a land situated at Patibulum Village, Kancheepuram District, Tamil Nadu, marking the permanent closure of the company's arrangement with DBS Bank India Limited in relation to the said property.
Orchid Pharma Ltd
Orchid Pharma Ltd has announced its Annual Report for FY 2025-26, along with the Notice of 33rd Annual General Meeting scheduled for September 29, 2026.
Orchid Pharma Ltd
Orchid Pharma Ltd has announced the notice of its 33rd Annual General Meeting for the financial year 2025-26.
Orchid Pharma Ltd
Orchid Pharma Ltd has announced the appointment of a cost auditor for FY 2026-27 and the change in designation of a director, Mr. Arjun Dhanuka, to Whole-Time Director.
Orchid Pharma Ltd
Orchid Pharma Ltd has announced the outcome of its Board meeting, where it has approved the appointment of a new Whole-Time Director, Mr. Arjun Dhanuka, and the appointment of a new Cost Auditor for FY 2026-27. The company has also scheduled its 33rd Annual General Meeting for September 29, 2026.
Orchid Pharma Ltd
Orchid Pharma Ltd's Q1 FY27 earnings conference call was held on August 21, 2026, with senior management discussing the company's financial performance for the quarter ended June 30, 2026. The call highlighted the challenges faced by the cephalosporin business, with revenue from operations at INR1,233 crores, a decline from INR1,398 crores in FY25. Gross margin moderated by approximately 4% to 32% in FY26 compared to 36% in FY25. The management remains disciplined on controllable costs.
Orchid Pharma Ltd
Orchid Pharma Ltd has uploaded the audio recording of its Q1 FY 2026-27 earnings call on its website.
Orchid Pharma Ltd
Orchid Pharma Ltd has released its Investors Presentation for Q1 of F.Y. 2026-27, ended on June 30, 2026, which includes the company's financial performance for the quarter.
Orchid Pharma Ltd
Orchid Pharma Ltd has announced the schedule of Analysts/Investors Earning Call for the Quarter-1 ended on June 30, 2026, to discuss the financial results/ performance of the Company.
Orchid Pharma Ltd
Orchid Pharma Ltd has filed a statement of deviation or variation for the quarter ended June 30, 2026, on the use of proceeds of funds raised through Qualified Institutional Placement (QIP). The company has modified the allocation of QIP proceeds due to changes in the business environment and to meet current strategic requirements.
Orchid Pharma Ltd
Orchid Pharma Ltd has released a Monitoring Agency Report for Q1 FY 2026-27, showing no deviation from the objects of the QIP issue. The report was issued by CARE Ratings Limited and covers the utilization of proceeds raised through the Qualified Institutions Placement.
Orchid Pharma Ltd
Orchid Pharma Ltd has announced revised audited financial results for the year ended March 31, 2026, following a scheme of merger with Dhanuka Laboratories Ltd. The company's net sales and total income have increased, while expenses have also risen. The profit before tax stands at ₹3,266.29 lakhs.
Orchid Pharma Ltd
Orchid Pharma Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, showing a net profit of ₹1,193.72 lakhs and ₹3,266.29 lakhs respectively.
Orchid Pharma Ltd
Orchid Pharma Ltd's board meeting approved unaudited financial results for Q1 FY 2026-27, ended June 30, 2026, with a net profit of ₹1,193.72 lakhs.
Orchid Pharma Ltd
Orchid Pharma Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 14/08/2026 to consider and approve Unaudited Limited reviewed financial results for the quarter ended June 30, 2026.
Orchid Pharma Ltd
Orchid Pharma Ltd has informed about the allotment of 4,45,86,052 equity shares to eligible shareholders of Dhanuka Laboratories Ltd as part of the scheme of amalgamation.